Han Sabrina H, Safeek Rachel, Ockerman Kyle, Trieu Nhan, Mars Patricia, Klenke Audrey, Furnas Heather, Sorice-Virk Sarah
Aesthet Surg J. 2023 Dec 14;44(1):60-67. doi: 10.1093/asj/sjad211.
Glucagon-like peptide 1 (GLP-1) agonists are a drug class used for the treatment of diabetes that have recently gained FDA approval for medical management of obesity. The off-label use of Ozempic (Novo Nordisk, Bagsværd, Denmark), the brand name of the GLP-1 agonist semaglutide, for cosmetic weight loss has been popularized by social media and celebrity influence. The aim of this study was to analyze with Google Trends (Alphabet Inc., Mountain View, CA) the recent search popularity of Ozempic and related GLP-1 agonists. The term "Ozempic" was analyzed with Google Trends. Search popularity was assessed in terms of relative search volume (RSV) over a 5-year period. Changes in RSV were further compared with other GLP-1 agonists, "Wegovy" (Novo NordisK) and "Mounjaro" (Eli Lilly and Company, Indianapolis, IN). Between March 2018 and February 2023, overall RSV in "Ozempic" grew exponentially in the United States. Simple linear regression analysis showed significantly increased RSV over time with an R2 of 0.915 and a regression coefficient of 0.957 (P < .001). When comparing "Ozempic," "Wegovy," and "Mounjaro" since June 2021 (FDA approval of Wegovy), Ozempic remained at the greatest RSV. One-way analysis of variance found statistically significant differences between the 3 search terms at all time points between December 2021 and February 2023 (P < .001). This study demonstrates a significant and growing public interest in Ozempic and related GLP-1 agonists. As the use of GLP-1 agonists for weight loss becomes more prevalent, plastic surgeons, particularly in the aesthetic setting, must be prepared for the downstream implications. Increased awareness, understanding, and further scientific studies led by plastic surgeons will help deliver the safest possible patient outcomes.
胰高血糖素样肽-1（GLP-1）激动剂是一类用于治疗糖尿病的药物，最近已获得美国食品药品监督管理局（FDA）批准用于肥胖症的医学管理。GLP-1激动剂司美格鲁肽的品牌名Ozempic（丹麦诺和诺德公司， Bagsværd）用于美容减肥的超说明书用药已因社交媒体和名人影响而流行开来。本研究的目的是利用谷歌趋势（谷歌公司，加利福尼亚州山景城）分析Ozempic及相关GLP-1激动剂近期的搜索热度。用谷歌趋势分析了“Ozempic”一词。根据5年期间的相对搜索量（RSV）评估搜索热度。将RSV的变化与其他GLP-1激动剂“Wegovy”（诺和诺德公司）和“Mounjaro”（礼来公司，印第安纳州印第安纳波利斯）进行了进一步比较。2018年3月至2023年2月期间，美国“Ozempic”的总体RSV呈指数增长。简单线性回归分析显示，RSV随时间显著增加，R2为0.915，回归系数为0.957（P <.001）。自2021年6月（Wegovy获得FDA批准）以来比较“Ozempic”“Wegovy”和“Mounjaro”时，Ozempic的RSV仍然最高。单向方差分析发现，在2021年12月至2023年2月的所有时间点，这3个搜索词之间存在统计学上的显著差异（P <.001）。本研究表明，公众对Ozempic及相关GLP-1激动剂的兴趣显著且不断增加。随着GLP-1激动剂用于减肥变得越来越普遍，整形外科医生，尤其是在美容领域，必须为其下游影响做好准备。整形外科医生提高认识、增进理解并开展进一步的科学研究将有助于实现尽可能安全的患者治疗效果。
